MOA image showing DepoFoam technology delivering bupivacaine during surgical procedure

EXPAREL delivers long-lasting pain control without the challenges of pumps and catheters

Avoid the burden of pumps and catheters with EXPAREL

Only EXPAREL provides long-lasting pain control in a single dose.

EXPAREL avoids the common problems associated with pumps and catheters1-4:

  • Migration1
  • Unpredictability/malfunction2-4
  • Patient compliance2
  • Leakage2,3
  • Infection4

Why risk toxicity with pumps and catheters?5

*Minimum local anesthetic threshold for CNS toxiicity is 2000 ng/ml.7
Data from a single-center cumulative dose toxicity study characterizing serum bupivacaine concentrations over 72 hours in patients undergoing a total knee arthroplasty.
Patients in the EXPAREL arm received EXPAREL 266 mg (20 mL) plus 30 mL of bupivacaine 0.5% as a periarticular injection (PAI). Patients in the continuous femoral nerve block arm received a bolus of 20 mL of
bupivacaine 0.5% followed by 8 mL/h bupivacaine 0.5% for 48 hours and a PAI of 30 mL of bupivacaine 0.5% during surgery.6

Compare the cost


133 mg (10 mL)=$175

266 mg (20 mL)=$325

Continuous catheter:

Average of $433.82 per patient for

device alone8

In the face of shortages,

EXPAREL requires significantly fewer local anesthetic resources than continuous catheters

EXPAREL delivers long-lasting pain control in a patient-friendly modality

  • No external devices attached to patients at discharge
  • No extra burden for patient to remove the catheter
  • No need for patient involvement once home
  • No unplanned phone calls related to patient compliance

CNS, central nervous system.